{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-118284","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.327216+00:00","generated_at":"2026-05-30T00:21:56.766716+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ocular Therapeutix Q3 net loss $36.5M; SOL-1 topline data expected Q4 2025","bullets":["Net loss of $36.5M ($0.22 diluted EPS) vs $0.5M loss in Q3 2023; R&D spend jumped to $37.1M.","Total net revenue $15.4M (+2.3% YoY); DEXTENZA full-year 2024 revenue guided $62-67M.","Cash $427.2M as of Sep 30, 2024, expected to fund operations into 2028.","SOL-1 fully randomized by YE 2024 (accelerated); topline data now expected Q4 2025.","SOL-R trial open for direct enrollment after FDA Type C response; NDA support confirmed."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-118284","json":"https://secwatch.observer/filing/0001104659-24-118284.json","markdown":"https://secwatch.observer/filing/0001104659-24-118284.md","text":"https://secwatch.observer/filing/0001104659-24-118284.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465924118284/0001104659-24-118284-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465924118284/tm2428320d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:21:56.766716+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}